Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy

**Background:** Pulmonary arterial hypertension (PAH) is described by proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance, right ventricular failure, and death. Research confirms long-term improvement in composite morbidity and mortality endpoints on some end...

Full description

Saved in:
Bibliographic Details
Main Authors: George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett, William Drake
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2018-01-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/9812
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.36469/9812

Similar Items